Evolus Inc (EOLS) - Total Assets
Based on the latest financial reports, Evolus Inc (EOLS) holds total assets worth $220.65 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Evolus Inc (EOLS) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Evolus Inc - Total Assets Trend (2015–2025)
This chart illustrates how Evolus Inc's total assets have evolved over time, based on quarterly financial data. Check EOLS cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Evolus Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Evolus Inc's total assets of $220.65 Million consist of 63.3% current assets and 36.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.8% |
| Accounts Receivable | $54.70 Million | 24.2% |
| Inventory | $26.96 Million | 11.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $48.04 Million | 21.3% |
| Goodwill | $21.21 Million | 9.4% |
Asset Composition Trend (2015–2025)
This chart illustrates how Evolus Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Evolus Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evolus Inc's current assets represent 63.3% of total assets in 2025, an increase from 4.9% in 2015.
- Cash Position: Cash and equivalents constituted 23.8% of total assets in 2025, up from 4.9% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, a decrease from 94.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 24.2% of total assets.
Evolus Inc Competitors by Total Assets
Key competitors of Evolus Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Evolus Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.04 | 2.34 | 1.85 |
| Quick Ratio | 1.68 | 2.16 | 1.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $70.90 Million | $75.48 Million | $74.60 Million |
Evolus Inc - Advanced Valuation Insights
This section examines the relationship between Evolus Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 53.71 |
| Latest Market Cap to Assets Ratio | 1.93 |
| Asset Growth Rate (YoY) | -2.9% |
| Total Assets | $225.87 Million |
| Market Capitalization | $436.62 Million USD |
Valuation Analysis
Above Book Valuation: The market values Evolus Inc's assets above their book value (1.93x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Evolus Inc's assets decreased by 2.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Evolus Inc (2015–2025)
The table below shows the annual total assets of Evolus Inc from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $225.87 Million | -2.88% |
| 2024-12-31 | $232.57 Million | +23.05% |
| 2023-12-31 | $189.00 Million | +6.19% |
| 2022-12-31 | $177.98 Million | -30.88% |
| 2021-12-31 | $257.48 Million | +23.16% |
| 2020-12-31 | $209.07 Million | -13.05% |
| 2019-12-31 | $240.44 Million | +39.92% |
| 2018-12-31 | $171.84 Million | +12.88% |
| 2017-12-31 | $152.23 Million | +96.44% |
| 2016-12-31 | $77.50 Million | -4.68% |
| 2015-12-31 | $81.30 Million | -- |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,… Read more